K2 Principal Fund’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

K2 Principal Fund’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-34,509	Closed	-$1.14K	–	340
2023 Q1	$1.14K	Buy	+34,509	New	+$2.38K	﹤0.01%	263

K2 Principal Fund's EUCRW Position: Q2 2023 in Review

K2 Principal Fund sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 34,509 shares — an estimated $1.14K sold.

K2 Principal Fund first reported a position in EUCRW in Q1 2023 and held it in 1 quarter. The position peaked at $1.14K in Q1 2023. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

K2 Principal Fund reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
K2 Principal Fund sold 34,509 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $1.14K.
K2 Principal Fund first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2023 and held it in 1 quarter.
K2 Principal Fund's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $1.14K in Q1 2023.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on K2 Principal Fund's 13F filing for Q2 2023, filed 15 Aug 2023.